It remains unclear what further policies, legislation and/or actions the Administration, Congress, or state governments will advance with respect to other drug pricing proposals or other healthcare regulations affecting pharmaceuticals, including the MFN EO, IRA and OB3 implementation, trade policies, or state laws affecting the 340B Program or Medicaid reimbursement that could ultimately be adopted more broadly. To the extent such actions reduce or modify coverage or reimbursement for our products, increase rebates or other costs, constrain pricing decisions, or otherwise limit product use, they would have an adverse effect on our business and results of operations.
All entries for: Oncology
April 30, 2026
Autolus Therapeutics
Layoffs
London
501-1,000 employees
In a move aimed at improving operational efficiency and cutting costs, London-based Autolus Therapeutics is letting go of about 13% of employees, the company announced April 29. The biotech, which develops autologous CAR T therapies, did not identify which locations the workforce reduction will affect but noted that it will impact all areas of the business. Autolus has a U.S. presence through its Gaithersburg, Maryland, office.
While the company said it’s cutting 13% of the workforce, it also noted that the reorganization includes “employee-related actions taken beginning in the second half of 2025.” When asked to clarify that statement, a spokesperson told BioSpace in an email that some employees were let go in the second half of last year, but “the number didn’t rise to the level of ‘material’ thus there was no announcement.” Those cuts, they added, count as part of the 13%.
The spokesperson did not identify how many people were laid off in the second half of last year. Autolus had 752 employees as of Dec. 31, according to its 2025 annual report.
Autolus plans to mostly complete the latest cuts by the third quarter and to save about $15 million on an annualized basis beginning in 2027, according to the announcement. The biotech expects its current and projected cash, cash equivalents and marketable securities will fund operations into the fourth quarter of 2027. Autolus had cash and cash equivalents of $104.1 million and marketable securities of $196.6 million as of Dec. 31, according to its annual report.
Disease Area: Oncology
Drug Type: Biologic
April 29, 2026
Ascentage Pharma Group International
Neutral Outlook
Rockville, MD
501-1,000 employees
For example, the IRA includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, such as directing the federal government to negotiate a maximum fair price for certain higher-cost single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to reduce out- of-pocket prescription drug costs for beneficiaries and impose new required discounts on manufacturers, among other changes.
Disease Area: Oncology, Rare Diseases
Drug Type: Small Molecule
April 28, 2026
Incyte Corp
Neutral Outlook
Wilmington, DE
1,001-5,000 employees
Further, in August 2022, the Inflation Reduction Act of 2022 was enacted, which includes provisions allowing the federal government to negotiate prices for certain high-expenditure single source Medicare drugs, to impose penalties and to implement a potential excise tax for manufacturers that fail to comply with the negotiation by offering a price that is not equal to or less than the negotiated “maximum fair price” under the law, and to impose rebate liability on manufacturers that take price increases that exceed inflation.
Disease Area: Hematology, Immune Diseases, Oncology
Drug Type: Biologic, Small Molecule
April 28, 2026
Novartis
Layoffs
Basel, Baselstadt
10,000+ employees
For the second month in a row, Novartis is chipping away at its East Hanover, New Jersey, workforce. The Swiss pharma is laying off 60 employees in the city effective July 24 to Nov. 20, according to a Worker Adjustment and Retraining Notification Act (WARN) notice. Novartis is also letting go of 114 people in East Hanover from June 26 to Nov. 27, according to a March WARN alert.
Novartis also trimmed its workforce in 2025, putting 1,069 employees—including 485 in East Hanover—on the chopping block over a multiyear period. The largest round of layoffs involved 550 employees in Switzerland who will be out of work by the end of 2027.
Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
April 10, 2026
Adlai Nortye Ltd.
Neutral Outlook
Alameda, CA
1,001-5,000 employees
On August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law. The IRA established the Medicare Drug Price Negotiation Program, under which the Centers for Medicare & Medicaid Services, or CMS, is authorized to negotiate maximum fair prices, or MFPs, for certain high-expenditure, single-source drugs without generic or biosimilar competition.
Disease Area: Oncology
Drug Type: Small Molecule
April 8, 2026
Nurix Therapeutics, Inc.
Neutral Outlook
Brisbane, CA
201-500 employees
Most notably, the Inflation Reduction Act (IRA), which was signed into law on August 16, 2022, allows Medicare to: beginning in 2026, establish a “maximum fair price” for a fixed number of pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services (CMS); and, as of 2023, penalize drug companies that raise prices for products covered under Medicare Parts B and D faster than inflation, among other reforms.
Disease Area: Immune Diseases, Oncology
Drug Type: Small Molecule
April 7, 2026
NovaBridge Biosciences
Negative Outlook
Rockville, MD
1-50 employees
Although full economic effect of the IRA on our business and the pharmaceutical industry in general is unknown at this time, it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.
Disease Area: Oncology, Rare Diseases
Drug Type: Biologic